| Product Revenue, Net |
3. Product Revenue, Net The Company derives substantially all of its product revenue, net from sales of ARCALYST in the United States, which was as follows: | | | | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | | June 30, | | June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | Product revenue, net | | $ | 243,600 | | $ | 156,797 | | $ | 457,866 | | $ | 294,582 |
The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the six months ended June 30, 2026: | | | | | | | | | | | | | | | Contractual | | Government | | | | | | | Adjustments | | Rebates | | Returns | | Total | Balance at December 31, 2025 | | $ | 4,559 | | $ | 11,883 | | $ | 3,124 | | $ | 19,566 | Current provisions relating to sales in the current year | | | 19,469 | | | 17,395 | | | 1,012 | | | 37,876 | Adjustments relating to prior years | | | (8) | | | (1,463) | | | (793) | | | (2,264) | Payments/returns relating to sales in the current year | | | (18,228) | | | (7,205) | | | — | | | (25,433) | Payments/returns relating to sales in the prior years | | | (4,551) | | | (7,522) | | | (131) | | | (12,204) | Balance at June 30, 2026 | | $ | 1,241 | | $ | 13,088 | | $ | 3,212 | | $ | 17,541 |
Total revenue-related reserves as of June 30, 2026 and December 31, 2025, included in the Company’s condensed consolidated balance sheets, are summarized as follows: | | | | | | | | | June 30, | | December 31, | | | 2026 | | 2025 | Components of accounts receivable | | $ | (1,160) | | $ | (831) | Components of other current liabilities | | | 18,701 | | | 20,397 | Total revenue-related reserves | | $ | 17,541 | | $ | 19,566 |
Substantially all of the Company’s trade accounts receivable arise from product revenue in the United States due from the Company’s third party logistics provider.
|